JPMorgan lowered the firm’s price target on Quest Diagnostics to $152 from $153 and keeps a Neutral rating on the shares ahead of the Q4 report. The analyst believes investors will be focused on five key areas when the labs report: volume trends, the impact of the Protecting Access to Medicare Act delay on 2024 margins, updates on recent acquisitions and strategy, and 2024 guidance and sequencing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics and Fitbit announce collaboration to study wearable devices
- Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
- Quest Diagnostics acquires assets of Steward Health Care’s outreach lab services
- Quest Diagnostics unit, Alliance Foundation Trials enter collaboration
- Quest Diagnostics initiated with an Equal Weight at Barclays